#DARZALEXFASPRO
LightNews LightNews
pharmaphorum.bsky.social
#JohnsonandJohnson's #Tecvayli has been approved as part of a #combinationregimen with its #Genmab-partnered #DarzalexFaspro as a second-line therapy for relapsed or refractory #multiplemyeloma, just 55 days after it was filed with the FDA.

pharmaphorum.com/news/jjs-tec...
March 6, 2026 at 12:40 PM
narrowit.bsky.social
J&J Multiple Myeloma Data Push Bispecific Combinations Earlier Johnson & Johnson reported Phase 3 MonumenTAL-3 results for TALVEY plus DARZALEX FASPRO combinations,...

https://www.narrowit.com/news/johnson-johnson-talvey-darzalex-monumental3-2026-06-13
#JohnsonJohnson #JNJ #TALVEY #DARZALEXFASPRO
Johnson & Johnson reports MonumenTAL-3 TALVEY and DARZALEX FASPRO data | Narrowit.com
Johnson & Johnson said TALVEY plus DARZALEX FASPRO combinations improved progression-free survival in the Phase 3 MonumenTAL-3 multiple myeloma study.
www.narrowit.com
June 13, 2026 at 4:19 PM